STRO vs XEL · rev $62.0M vs P/E 20, $39.33B cap
Sutro Biopharma (STRO) versus Xcel Energy Inc (XEL) — a side-by-side from cached financials, not a winner call.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Xcel Energy Inc (XEL) is a utilities - regulated electric company listed on US.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
XEL does not have a complete income-statement cache yet.
STRO currently screens at market cap $470.8M. XEL currently screens at market cap $39.33B and trailing P/E 20.1.
Not investment advice. Open the STRO and XEL stock pages for the full models.
Not investment advice.